LGM
BMRN icon

Logos Global Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Logos Global Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-100,000
Closed -$8.67M – 61
2023
Q2 		$8.67M Sell
100,000
-50,000
-33% -$4.71M 1.18% 27
2023
Q1 		$14.6M Buy
+150,000
New +$15.6M 2.09% 20

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Logos Global Management's BMRN Position: Q3 2023 in Review

Logos Global Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 100,000 shares — an estimated $8.67M sold.

Logos Global Management first reported a position in BMRN in Q1 2023 and held it in 2 quarters. The position peaked at $14.6M in Q1 2023. 519 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

  • Logos Global Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Logos Global Management sold 100,000 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $8.67M.
  • Logos Global Management first reported a position in BioMarin Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Logos Global Management's BioMarin Pharmaceuticals position peaked at $14.6M in Q1 2023.
  • 519 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on Logos Global Management's 13F filing for Q3 2023, filed 14 Nov 2023.